Busulfan, melphalan, and bortezomib versus high-dose melphalan as a conditioning regimen for autologous transplants in multiple myeloma: Long term follow up of a novel conditioning regimen.
Study #: MM18-04
Study Status: Published
Presentation(s)
2019, ASH (Poster)